Emcure Pharma eyes acquisition-led growth

Emcure Pharmaceuticals is aiming to be among the top-five drug firms in India in the next five to seven years as it also eyes acquisitions for growth going forward, a top company official said, while adding that the company will continue to look for acquisitions for growth, another important growth opportunity will be in-licensing, going forward. The company is currently developing mRNA vaccine for Covid-19 through its subsidiary, Gennova Biopharmaceuticals. "We are now currently in the top-10 pharma companies in India and I would like to take the company to the top-five in the next five to seven years for sure. That is one thing which is the driving force for me," Emcure Pharmaceuticals Managing Director and CEO Satish Mehta said.

On being asked about the status of the vaccine, company's subsidiary Gennova is developing for Covid-19, Mehta said, "We are developing the vaccine and have completed the phase-1 trials. We are currently in the process of evaluating the results for safety and efficacy, and very shortly we should be submitting the findings to the Central Drugs Standard Control Organisation (CDSCO) and then we will go for phase-2 and phase-3 trials."